Christiansen, C.: Prophylactic treatment for age-related bone loss in women. In, Osteoporosis 2, Copenhagen International Symposium on Osteoporosis, June 3–8, 1984, pp 587–593.Christiansen C. Prophylactic treatment for age-related bone loss in women. In: Osteoporosis C. Christiansen, CD. ...
Treatment of bone loss in proximal femurs of postmenopausal osteoporotic women with AGN1 local osteo-enhancement procedure (LOEP) increases hip bone mineral density and hip strength: a long-term prospective cohort studyBone mineral densityFemoral strength...
Osteoporosis is one of the most frequent diseases in postmenopausal women, leading to an increased fracture risk due to the physiologic loss of the bone protective effects of estrogen. Hereby, several risk factors for fracture such as prevalent fracture, low bone mineral density (BMD), age, low...
While most older patients with osteoporosis are treated with antiresorptive bisphosphonates such as alendronate, risedronate, ibandronate, and zoledronic acid, such drugs have side effects, remain in bone for extended periods, and lead to poor adherence to chronic treatment. Denosumab is a humanized mo...
Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2‐year Clinical TrialZoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2‐year Clinical TrialBONE MINERAL DENSITYDENOSUMAB...
Cancer Treatment–related Bone Loss and Osteoporosis: A Concern for Women with Breast Cancerincrease bone loss and frac- ture rates, but this effect is reversible clodronate, ibandronate,pamidronate, risedronate, and zoledronic acid have protective effects against bone healthcareproviders.2 These ...
In women with advanced breast cancer, approximately three-quarters develop metastases to the bone, with a median survival after diagnosis of 2–3 years. Receptor activator of nuclear factor-κB (RANK) and RANK ligand (RANKL) belong to a signal pathway highly implicated in the development of bone...
摘要: SummaryBACKGROUND AND OBJECTIVE Amenorrhoea in women of reproductive age causes loss of bone mineral. This study assessed the effect of treatment of amenorrhoea on bone mineral density.DOI: 10.1111/j.1365-2265.1994.tb02545.x 被引量: 112 ...
1 An increase in the survival time may increase the incidence of bone metastasis. Recently, cancer chemotherapy has also made considerable progress in increasing survival of patients with far-advanced cancer. For example, gefitinib improved disease-free survival of epidermal growth factor receptor (...
Loss of sexual desire in the postmenopausal woman. J Sex Med. 2007;4(2):395-405.PubMedGoogle ScholarCrossref 18. Sprout Pharmaceuticals. Flibanserin for the treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women: NDA 022526: Advisory Committee Briefing Document. June 4, 2015. ...